Jenalle Dion, Founder of Wakeful Travel shares the importance and practice of journalling for psychedelic integration
Similar Posts
Numinus CEO Discussion: a LEADER in Psychedelic-Assisted Therapy? ( NUMI / LKYSF Stock)
Numinus Wellness (TSX.V: NUMI), (OTC: LKYSF), has been a constant topic of conversation on this channel. NUMI is a company working on psychedelic-assisted therapy: with MDMA for PTSD, in collaboration with MAPS; Ketamine Therapy for Depression; and Psilocybin therapy for addiction, That’s why we decided to invite NUMI’s CEO, Payton Nyquvest. I hope you all enjoy!
Timestamps
1:00 – What is Numinus’ mission?
2:37 – Numinus’ partnership with MAPS to treat PTSD with MDMA
9:54 – Numinus treating addiction with Psilocybin
13:35 – Using ketamine to treat Depression
18:45 – Growing natural Psilocybin vs Synthetic versions?
21:45 -The 5-year plan
26:38 – What will revenues look like?
Enjoy the episode!
Check out our website:
ThePsychedelicInvestor.com
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Numinus #NUMIStock
#numinus #numi #numistock
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
CYBIN CEO Doug Drysdale On How CYB-003 Is Better Than Psilocybin | Next Gen Psychedelics
In this episode of the Spotlight On, James Hallifax from…
MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
Stay tuned for more updates!
In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.
MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.
Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.
The results were very positive, though perhaps not paradigm shifting — yet.
The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.
The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.
Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.
Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”
In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”
Interested in reading the article? Click here: 👇
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/
#MindMed #Anxiety #MNMD
Interview With Lauren Taus
In this episode of the Psychedelic Spotlight podcast we speak with Lauren Taus who is the Founder of INBodied Life, who’s focus is on integrating modern science and ancient wisdom to support transformation.
Interview With Henri Sant-Cassia, The Conscious Fund
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founding Partner at The Conscious Fund, Henri Sant-Cassia.